NurExone Biologic Inc. finalized a lease and constructing agreement for nearly 200 square meters of laboratories and office space on the campus of the prestigious Israel Institute of Technology (?Technion?). The lease period extends until December 31, 2028, with an option to extend for an additional five years. The Technion?s commitment to science research and biotech innovation are reflected in the decision to allocate a new facility on the university?s campus to the Company.

This exclusive location will provide NurExone with ongoing access to top talent, resources and human capital from the university. The new facilities will play a pivotal role in driving the development of the Company?s revolutionary ExoPTEN and ExoTherapy platform, positioning NurExone at the forefront of exosome-based therapies advancements. In the pursuit of constructing a cutting-edge facility that will cater to the needs of the Company and its prospective collaboration partners, the Company has signed a construction agreement with Biopharmax Group Ltd. ("Biopharmax").

Construction of the state-of-the-art laboratories and offices is slated for completion within a 12-week period.